Robert Wasserman
Stock Analyst at Benchmark
(3.27)
# 1,084
Out of 4,984 analysts
108
Total ratings
50%
Success rate
1.95%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.24 | +519.83% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $51.52 | +45.57% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $6.90 | +117.39% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.62 | +270.37% | 9 | May 12, 2025 | |
| ITGR Integer Holdings | Maintains: Buy | $150 → $140 | $102.69 | +36.33% | 11 | Apr 25, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $36.74 | -4.74% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.57 | - | 6 | Mar 3, 2025 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $75 | $75.81 | -1.07% | 9 | Feb 20, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $25.59 | +17.26% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $2.45 | +226.53% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $4.27 | +17.10% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $7.79 | +54.04% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.35 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $119.39 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $49.37 | -8.85% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.47 | -10.51% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.21 | +1,834.24% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $3.44 | +2,080.23% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $192.94 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $472.64 | +22.71% | 1 | Jul 16, 2021 |
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.24
Upside: +519.83%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $51.52
Upside: +45.57%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.90
Upside: +117.39%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.62
Upside: +270.37%
Integer Holdings
Apr 25, 2025
Maintains: Buy
Price Target: $150 → $140
Current: $102.69
Upside: +36.33%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $36.74
Upside: -4.74%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.57
Upside: -
Halozyme Therapeutics
Feb 20, 2025
Reiterates: Buy
Price Target: $75
Current: $75.81
Upside: -1.07%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $25.59
Upside: +17.26%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.45
Upside: +226.53%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $4.27
Upside: +17.10%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $7.79
Upside: +54.04%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.35
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $119.39
Upside: -
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $49.37
Upside: -8.85%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.47
Upside: -10.51%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.21
Upside: +1,834.24%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $3.44
Upside: +2,080.23%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $192.94
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $472.64
Upside: +22.71%